Mohamad Mohty Jean-Luc Harousseau. Handbook of Multiple Myeloma. Springer

Transcription

1 Mohamad Mohty Jean-Luc Harousseau Handbook of Multiple Myeloma

2 Mohamad Mohty Jean-Luc Harousseau Handbook of Multiple Myeloma

3

4 Mohamad Mohty, MD, PhD Université Pierre and Marie Curie Hospital Saint-Antoine Paris, France Jean-Luc Harousseau, MD Centre René Gauducheau Nantes Atlantique (Saint-Herblain), France Handbook of Multiple Myeloma

5 Editors Mohamad Mohty MD, PhD Clinical Hematology and Cellular Therapy Department Université Pierre and Marie Curie Hospital Saint-Antoine Paris, France Jean-Luc Harousseau MD Department of Hematology Centre René Gauducheau Nantes Atlantique (Saint-Herblain) France ISBN ISBN (ebook) DOI / Springer Cham Heidelberg New York Dordrecht London International Publishing Switzerland 2015 This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed. Exempted from this legal reservation are brief excerpts in connection with reviews or scholarly analysis or material supplied specifically for the purpose of being entered and executed on a computer system, for exclusive use by the purchaser of the work. Duplication of this publication or parts thereof is permitted only under the provisions of the Copyright Law of the Publisher s location, in its current version, and permission for use must always be obtained from Springer. Permissions for use may be obtained through RightsLink at the Copyright Clearance Center. Violations are liable to prosecution under the respective Copyright Law. The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use. While the advice and information in this book are believed to be true and accurate at the date of publication, neither the authors nor the editors nor the publisher can accept any legal responsibility for any errors or omissions that may be made. The publisher makes no warranty, express or implied, with respect to the material contained herein. Printed on acid-free paper Adis is a brand of Springer Springer is part of Springer Science+Business Media ( Project editor: Laura Hajba Contributors Hervé Avet-Loiseau MD Joan Bladé MD, PhD Eileen M Boyle MD Jill Corre PharmD, PhD Michel Delforge MD, PhD Hélène Demarquette MB Thierry Facon MD Carlos Fernández de Larrea MD, PhD Stéphanie Guidez MD Charles Herbaux MD Charline Legrand MB Xavier Leleu MD, PhD Florent Malard MD, PhD Evangelos Terpos MD, PhD

6 Contents Author biographies Abbreviations Introduction vii xv xxi 1 Pathophysiology 1 Hervé Avet-Loiseau and Jill Corre Chromosomal aberrations 1 Changes in gene expression 4 Bone marrow microenvironment and cytokine network 5 References 11 2 Diagnosis and staging 15 Carlos Fernández de Larrea and Joan Bladé Diagnostic criteria 15 Classification 16 Prognosis 19 Imaging 21 Response criteria 21 Minimal residual disease 25 Acknowledgement 27 References 27 3 Treatment of transplant-eligible patients 29 Mohamad Mohty, Florent Malard, and Jean-Luc Harousseau Induction therapy 29 Autologous transplantation 31 Consolidation 32 Maintenance 34 Allogeneic transplantation 36 References 38 v

7 vi contents 4 Treatment of elderly patients with myeloma 41 Eileen M Boyle, Charline Legrand, Hélène Demarquette, Stéphanie Guidez Charles Herbaux, Xavier Leleu, and Thierry Facon Introduction 41 Epidemiology 41 Biological and clinical features 42 Defining aims 43 What to aim for? 44 Disease-specific treatment options 44 Tailoring the treatment to the patient 50 Supportive care 56 Conclusion and perspectives 58 References 59 5 Treatment of relapsed multiple myeloma 65 Michel Delforge General considerations 65 Immediate treatment initiation or watchful waiting 66 To re-treat or not 68 Role of allogeneic transplantation 70 Optimizing drug-based treatment at relapse 70 Supportive care 73 Conclusion 74 References 74 6 Bone disease 79 Evangelos Terpos Introduction 79 Biology of multiple myeloma bone disease 79 Therapy 82 References 88